Leukemia News and Research RSS Feed - Leukemia News and Research

Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.
MD Anderson study sheds light on little-known protein complex

MD Anderson study sheds light on little-known protein complex

A study at The University of Texas MD Anderson Cancer Center led by Mong-Hong Lee, Ph.D., a professor of molecular and cellular oncology, has demonstrated the significance of CSN6 in regulating Myc which may very well open up a new pathway for treating and killing tumors. [More]
BerGenBio's BGB324 gets orphan-drug designation from FDA for AML treatment

BerGenBio's BGB324 gets orphan-drug designation from FDA for AML treatment

BerGenBio AS, an oncology biopharmaceutical company, today announces that the US Food and Drug Administration has granted orphan-drug designation for BGB324 for treatment of acute myeloid leukaemia (AML). [More]
Strategy to stem infections in livestock, endangered species

Strategy to stem infections in livestock, endangered species

When a viral infection spread through five genetically identical mice in a row, the virus replicated faster and became more virulent or severe. But when the infection spread one-by-one through five genetically diverse mice, the virus had trouble adapting and became less virulent. [More]
3SBio enters into exclusive license agreement with PharmAbcine for Tanibirumab

3SBio enters into exclusive license agreement with PharmAbcine for Tanibirumab

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced it has entered into an exclusive license with PharmAbcine, Inc. for the development, manufacturing and marketing of Tanibirumab, an anti-VEGFR2/KDR antibody for cancer in the territory of Greater China (including Mainland China, Taiwan, Hong Kong and Macau) and several emerging countries, including Thailand, Brazil and Russia. [More]
FDA grants Orphan Drug Designation to Juno's JCAR015 leukemia T cell product candidate

FDA grants Orphan Drug Designation to Juno's JCAR015 leukemia T cell product candidate

Juno Therapeutics, Inc. announced today that the FDA has granted Orphan Drug Designation to its JCAR015 chimeric antigen receptor product candidate. The designation was granted for treatment of acute lymphoblastic leukemia. JCAR015 Phase I trials are currently underway at Juno's collaboration partner, Memorial Sloane Kettering Cancer Center. [More]
Cholesterol-fighting statins inhibit uterine fibroid tumors that account for 50% of hysterectomies

Cholesterol-fighting statins inhibit uterine fibroid tumors that account for 50% of hysterectomies

Researchers at the University of Texas Medical Branch at Galveston, in collaboration with The University of Texas Health Science Center at Houston (UTHealth), Baylor College of Medicine and the Georgia Regents University, report for the first time that the cholesterol-lowering drug simvastatin inhibits the growth of human uterine fibroid tumors. [More]
Researchers find key mechanism that could lead to new effective treatments for leukemias

Researchers find key mechanism that could lead to new effective treatments for leukemias

Researchers have identified two proteins that appear crucial to the development -- and patient relapse -- of acute myeloid leukemia. They have also shown they can block the development of leukemia by targeting those proteins. [More]
Scientists use Rapid Heme Panel test to identify right treatment for leukemia, other blood cancers

Scientists use Rapid Heme Panel test to identify right treatment for leukemia, other blood cancers

For patients with aggressive types of leukemia and other blood cancers, quickly identifying and starting the right treatment can make all the difference. [More]
U of T, Chematria and IBM partner to find new treatments for Ebola virus

U of T, Chematria and IBM partner to find new treatments for Ebola virus

The University of Toronto, Chematria and IBM are combining forces in a quest to find new treatments for the Ebola virus. [More]
Actimab-A extends overall survival, reduces bone marrow blasts in older AML patients

Actimab-A extends overall survival, reduces bone marrow blasts in older AML patients

Interim data from an ongoing Phase I/II trial of Actimab-A, an innovative targeted payload immunotherapy, demonstrated a number of positive findings, including extension of overall survival and significant reductions in bone marrow blasts in older patients with newly diagnosed Acute Myeloid Leukemia (AML). [More]
Seattle Children's starts patient enrollment for immunotherapy clinical trial for neuroblastoma

Seattle Children's starts patient enrollment for immunotherapy clinical trial for neuroblastoma

Seattle Children's today announced the opening of patient enrollment for its new cellular immunotherapy clinical research trial designed to induce remission in children suffering from neuroblastoma, one of the deadliest forms of childhood cancer. [More]
Researchers develop 'smart bomb' to attack B-lineage ALL

Researchers develop 'smart bomb' to attack B-lineage ALL

Fatih Uckun, Jianjun Cheng and their colleagues have taken the first steps towards developing a so-called "smart bomb" to attack the most common and deadly form of childhood cancer — called B-lineage acute lymphoblastic leukemia (ALL). [More]
M2Gen, Moffitt to serve as Central Laboratory and Biorepository for The National MDS Study

M2Gen, Moffitt to serve as Central Laboratory and Biorepository for The National MDS Study

Moffitt Cancer Center and M2Gen have been awarded a contract from the National Institutes of Health's National Heart, Lung, and Blood Institute (NHLBI) to serve as the Central Laboratory and Biorepository for The National Myelodysplastic Syndromes Natural History Study (The National MDS Study). [More]
New correlation found between specific molecular features of CLL and patients with different prognosis

New correlation found between specific molecular features of CLL and patients with different prognosis

If chronic lymphocytic leukemia patients with a good or poor prognosis could be identified already at the time of diagnosis, physicians would have better possibilities to adjust their therapeutic and follow-up strategies. Now researchers at Uppsala University, together with international colleagues, have discovered a new correlation between specific molecular features of the disease and subgroups of patients with different prognosis. [More]
Loyola study finds radiation as a risk factor for young people with meningioma

Loyola study finds radiation as a risk factor for young people with meningioma

In people under age 30, radiation is a risk factor for a type of brain tumor called a meningioma, a Loyola University Medical Center study has found. [More]
AstraZeneca, Pharmacyclics partner to evaluate efficacy of IMBRUVICA for solid tumors

AstraZeneca, Pharmacyclics partner to evaluate efficacy of IMBRUVICA for solid tumors

AstraZeneca and Pharmacyclics, Inc. today announced that they have entered into a clinical trial collaboration to evaluate a novel combination therapy targeting solid tumors. [More]
Melbourne researchers reveal key steps involved in programmed cell death

Melbourne researchers reveal key steps involved in programmed cell death

Melbourne researchers have uncovered key steps involved in programmed cell death, offering new targets for the treatment of diseases including lupus, cancers and neurodegenerative diseases. [More]
Stem cell technologies market expected to show annual increase of 16.2% over 2010-2020

Stem cell technologies market expected to show annual increase of 16.2% over 2010-2020

Though therapies are in their nascent phase, sales of stem cell technologies are expected to show an annual increase of 16.2% over the 2010-2020 period, reaching an expected market value of nearly $1 billion, according to Kalorama Information's report, Stem Cell Therapeutics Markets. [More]
BloodCenter of Wisconsin announces availability of cancer mutation HemeOnc Panel

BloodCenter of Wisconsin announces availability of cancer mutation HemeOnc Panel

BloodCenter of Wisconsin's Diagnostic Laboratories today announced the availability of a comprehensive cancer mutation HemeOnc Panel using next generation sequencing (NGS) technology. The NGS panel developed by BloodCenter of Wisconsin is designed to detect variants in 30 genes that are either prognostic or diagnostic for 10 different myeloid hematologic malignancies. [More]

Kiadis Pharma's ATIR product receives EMA's ODD for treatment of acute myeloid leukemia

Kiadis Pharma B.V., a clinical stage biopharmaceutical company developing T-cell immunotherapy treatments for blood cancers, today announces that its lead product ATIR has been granted Orphan Drug Designation (ODD) by the European Medicines Agency for the treatment of acute myeloid leukemia (AML). [More]